The aim of the present randomized double-blind placebo-controlled trial is to evaluate the efficacy of a probiotic formulation, containing the probiotic strain Lacticaseibacillus rhamnosus CA15 (DSM 33960), in the treatment of vaginal dysbiosis in terms of: (i) modulation of the microbiota (increase of lactobacilli and decrease of pathogens), (ii) reduction of clinical signs of inflammation, (iii) improvement of quality of life.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Microbiota
Timeframe: Baseline; end of the treatment (10 days); wash-out (30 days)
Symptomatology
Timeframe: Baseline; end of the treatment (10 days); wash-out (30 days)
Sign
Timeframe: Baseline; end of the treatment (10 days); wash-out (30 days)